Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Ursa Brown-Glaberman"'
Autor:
Cindy K. Blair, Elizabeth M. Harding, Prajakta Adsul, Sara Moran, Dolores Guest, Kathy Clough, Andrew L. Sussman, Dorothy Duff, Linda S. Cook, Joseph Rodman, Zoneddy Dayao, Ursa Brown-Glaberman, Towela V. King, V. Shane Pankratz, Eduardo Servin, Sally Davis, Wendy Demark-Wahnefried
Publikováno v:
Contemporary Clinical Trials Communications, Vol 21, Iss , Pp 100741- (2021)
Few diet and physical activity evidence-based interventions have been routinely used in community settings to achieve population health outcomes. Adapting interventions to fit the implementation context is important to achieve the desired results. Ha
Externí odkaz:
https://doaj.org/article/cceb6cdfbbb446eeb5ab643e854fb150
Autor:
Yi Liu, Capucine Baldini, Jameel Muzaffar, David Hong, Olivier Rixe, Christophe Massard, Timothy Yap, Solmaz Sahebjam, Ursa Brown-Glaberman, Andreea Varga, Sergey Efuni, Barbara Kapelan, Eniola Ogunmefun, Tomonori Tayama, Henry Zhao, Denis Healy, Robert Latek, Daisuke Nakashima, Emrullah Yilmaz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/661ac478574745f894f0fe0eb1116527
Autor:
Cindy K. Blair, Prajakta Adsul, Dolores D. Guest, Andrew L. Sussman, Linda S. Cook, Elizabeth M. Harding, Joseph Rodman, Dorothy Duff, Ellen Burgess, Karen Quezada, Ursa Brown-Glaberman, Towela V. King, Erika Baca, Zoneddy Dayao, Vernon Shane Pankratz, Sally Davis, Wendy Demark-Wahnefried
Publikováno v:
Nutrients, Vol 13, Iss 7, p 2319 (2021)
Harvest for Health is a home-based vegetable gardening intervention that pairs cancer survivors with Master Gardeners from the Cooperative Extension System. Initially developed and tested in Alabama, the program was adapted for the different climate,
Externí odkaz:
https://doaj.org/article/42ddd5dce9ab42218a47cebca5e5c29a
Autor:
Patrick Dillon, Reva Basho, Hyo S. Han, Hans-Christian Kolberg, Katherine Tkaczuk, George Zahrah, Maria Gion, Herman Voss, Jane Meisel, Timothy Pluard, Jenny Fox, Mafalda Oliveira, Ursa Brown-Glaberman, Erica Stringer-Reasor, Luis Manso, Sherko Küemmel, Lin Chi Chen, Sheng Wu, Brandon Croft, Valentina Boni
Publikováno v:
Cancer Research. 83:OT1-03
Background Patients with metastatic triple-negative breast cancer (mTNBC) have a poor prognosis. Treatment combinations of anti-programmed death protein 1 (anti–PD-1) agents with chemotherapy have shown promise in mTNBC. Ladiratuzumab vedotin (LV)
Autor:
Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck, Jose Mayordomo, Jennifer Diamond, Peter Kabos, Virginia F. Borges
Publikováno v:
Cancer Research. 82:P1-18
Background: The phase IB/II clinical trial of tucatinib, palbociclib and letrozole (NCT03054363) showed activity in heavily pretreated patients (pts) with HR+/HER2+ metastatic breast cancer (Shagisultanova et. al, Cancer Res 2021:81(4), PS10-03). Her
Autor:
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Margaret Block, Kimberly A Morley, Chirag R Jani, Craig Mescher, Shabana J Dewani, Ursa Brown-Glaberman, Lisa E Flaum, Erica L Mayer, William M Sikov, Eve T Rodler, Angela M DeMichele, Joseph A Sparano, Antonio C Wolff, Kathy D Miller, Lynne I Wagner
Publikováno v:
Cancer Research. 82:P4-10
Background: Understanding health-related quality of life (HRQOL), including side effects, is critical to guide supportive care during chemotherapy. The EA1131 trial demonstrated that Platinum (Plat) was unlikely to improve outcomes compared to capeci
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Michael A, Williams, Dianne R, Nielsen, Zoneddy, Dayao, Ursa, Brown-Glaberman, Bernard, Tawfik
Publikováno v:
Oncology nursing forum. 49(6)
To assess the efficacy of the University of New Mexico Comprehensive Cancer Center's (UNMCCC's) breast cancer nurse navigator (BCNN) program in addressing gaps in cancer care for an underserved, rural, and economically disadvantaged population.54 nav
Autor:
Ursa Brown-Glaberman, Maaike de Boer, Denise A. Yardley, Jeffrey L. Nordstrom, Sung Bae Kim, Erik Jakobsen, Jean Marc Ferrero, Scott Koenig, William J. Gradishar, Seock-Ah Im, Javier Cortes, Gail S. Wright, Ezio Bonvini, Cristina Saura, Michelino De Laurentiis, Bella Kaufman, Sutton Edlich, Hope S. Rugo, Christelle Levy, Fatima Cardoso, Antonino Musolino, Peter A. Fasching, Mark D. Pegram, Orit Freedman, Santiago Escrivá-de-Romaní, Shengyan Hong, Rinat Yerushalmi, Edwin P. Rock, Giuseppe Curigliano, Katarína Petráková
Publikováno v:
SOPHIA Study Group 2021, ' Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer : A Phase 3 Randomized Clinical Trial ', JAMA Oncology, vol. 7, no. 4, pp. 573-584 . https://doi.org/10.1001/jamaoncol.2020.7932
JAMA Oncology, 7(4), 573-584. American Medical Association
JAMA Oncol
Scientia
JAMA Oncology, 7(4), 573-584. American Medical Association
JAMA Oncol
Scientia
Advanced Breast Cancer; Efficacy; Margetuximab Cáncer de mama avanzado; Eficacia; Margetuximab Càncer de mama avançat; Eficàcia; Margetuximab Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains typically incurable wit
Autor:
Ursa Brown-Glaberman, Jose I. Mayordomo, William J. Gradishar, Jennifer R. Diamond, Andrew Brenner, Pavani Chalasani, Alison Stopeck, Virginia F. Borges, Peter Kabos, Elena Shagisultanova
Publikováno v:
Cancer Research. 81:PS10-03
Background: In hormone receptor-positive / HER2-positive (HR+/HER2+) breast cancer, the HER2 and estrogen receptor (ER) signals merge on the cyclin D1-CDK4/6-RB1 pathway. Thus, a combined pharmacological intervention with individual drugs targeting H